Dual Antiplatelet Therapy is a cornerstone of management for patients after myocardial infarction or coronary stenting. Recent large randomized trials consistently indicate reduction in risk of recurrent myocardial infarction, yet increased risk of bleeding when these medications are given beyond one year. The results of recent trials and their application to patient care using new decision tools will be discussed.
Laura Mauri, MD, MSc
Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Chief Scientific Officer, Harvard Clinical Research Institute
Created by
